论文部分内容阅读
目的探讨肠内营养支持在卵巢癌化疗患者中临床应用价值,为卵巢癌患者的肠内营养支持提供依据。方法选取2011年1月-2013年1月在该院行卵巢癌术后化疗的患者105例为研究对象。采用NRS2002营养风险筛查法进行筛查,将其中60例存在营养风险(NRS评分≥3分)的患者作为阳性组,其余45例作为阴性组;将60例阳性组患者随机分为治疗组和对照组,每组各30例。阳性组患者均采用紫杉醇/顺铂(TC)化疗方案,其中治疗组给予肠内营养治疗,连续3~6个月。监测两组患者人体测量值和营养生化指标的变化情况。结果治疗组人体测量值各指标的下降情况优于对照组,其中以体重指数、体重最为敏感,差异均具有统计学意义(P<0.05);治疗组营养生化指标缓解情况优于对照组,以对白蛋白、前白蛋白的影响最为显著,差异均具有统计学意义(P<0.05)。结论肠内营养支持可明显改善卵巢癌术后化疗患者的营养状态,适合临床推广与应用。
Objective To investigate the clinical value of enteral nutrition support in patients with ovarian cancer and to provide basis for enteral nutrition support in patients with ovarian cancer. Methods From January 2011 to January 2013, 105 patients with postoperative chemotherapy of ovarian cancer in this hospital were selected as the research object. NRS2002 nutritional risk screening screening method, of which 60 cases of nutritional risk (NRS score ≥ 3 points) of patients as a positive group, and the remaining 45 cases as a negative group; the 60 positive patients were randomly divided into treatment group and Control group, 30 cases in each group. Patients in the positive group were treated with paclitaxel / cisplatin (TC) chemotherapy, in which the treatment group was given enteral nutrition for 3 to 6 months. The changes of anthropometric parameters and nutrition and biochemical indexes in two groups were monitored. Results Compared with the control group, the decrease of the measured value of the human body in the treatment group was more significant than that of the control group (P <0.05). The alleviation of nutrition and biochemical indexes in the treatment group was better than that in the control group The effects of albumin and prealbumin were the most significant, the differences were statistically significant (P <0.05). Conclusion Enteral nutrition can significantly improve the nutritional status of patients with postoperative chemotherapy for ovarian cancer, which is suitable for clinical application and promotion.